Jennifer A Lockridge

US Patent:

20030216335, Nov 20, 2003

Filed:

Nov 27, 2002

Appl. No.:

10/306747

Inventors:

Jennifer Lockridge - Westminster CO, US
Pamela Pavco - Lafayette CO, US
Gilad Gordon - Boulder CO, US

International Classification:

A61K048/00

US Classification:

514/044000

Abstract:

The present invention relates to nucleic acid molecules, including dsRNA, siRNA, antisense, 2,5-A chimeras, aptamers, and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, and allozymes, which modulate the expression of vascular endothelial growth factor receptor (VEGF) and/or vascular endothelial growth factor receptor (VEGFr) genes for the treatment and/or diagnosis of female reproductive disorders and conditions, including but not limited to endometriosis, endometrial carcinoma, gynecologic bleeding disorders, irregular menstrual cycles, ovulation, premenstrual syndrome (PMS), and menopausal dysfunction.

US Patent:

20040142895, Jul 22, 2004

Filed:

Dec 2, 2003

Appl. No.:

10/726236

Inventors:

Jennifer Lockridge - Westminster CO, US
Pamela Pavco - Lafayette CO, US

Assignee:

Sirna Therapeutics, Inc. - Boulder CO

International Classification:

A61K048/00

US Classification:

514/044000

Abstract:

The present invention relates to nucleic acid molecules, including dsRNA, siRNA, antisense, 2,5-A chimeras, aptamers, and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, and allozymes, which modulate the expression of vascular endothelial growth factor receptor (VEGF) and/or vascular endothelial growth factor receptor (VEGFr) genes for the treatment and/or diagnosis of female reproductive disorders and conditions, including but not limited to endometriosis, endometrial carcinoma, gynecologic bleeding disorders, irregular menstrual cycles, ovulation, premenstrual syndrome (PMS), and menopausal dysfunction.

US Patent:

20040220128, Nov 4, 2004

Filed:

Nov 13, 2003

Appl. No.:

10/712633

Inventors:

Pamela Pavco - Lafayette CO, US
Jennifer Lockridge - Westminster CO, US
James McSwiggen - Boulder CO, US

International Classification:

A61K048/00
C07H021/02

US Classification:

514/044000, 536/023100

Abstract:

The present invention relates to nucleic acid molecules, including dsRNA, siRNA, antisense, 2,5-A chimeras, aptamers, and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, and allozymes, which modulate the expression of vascular endothelial growth factor receptor (VEGF) and/or vascular endothelial growth factor receptor (VEGFr) genes for the treatment and/or diagnosis of diseases and conditions associated with angiogenesis, such as cancer, tumor angiogenesis, or ocular indications such as diabetic retinopathy, or age related macular degeneration, proliferative diabetic retinopathy, hypoxia-induced angiogenesis, rheumatoid arthritis, psoriasis, wound healing, and female reproductive disorders and conditions, including but not limited to endometriosis, endometrial carcinoma, gynecologic bleeding disorders, irregular menstrual cycles, ovulation, premenstrual syndrome (PMS), and menopausal dysfunction.